Reports Q4 revenue $3,000, consensus $10,000. “The future of obesity care isn’t just about losing weight-it’s about keeping it off,” said Harith Rajagopalan, co-founder and CEO of Fractyl Health (GUTS). “At Fractyl, we are pioneering a new treatment paradigm that moves beyond short-term fixes to deliver lasting metabolic solutions. Our goal is to provide patients and physicians with something they don’t have today: a science-driven approach to long-term weight maintenance and metabolic health. With multiple key anticipated clinical milestones ahead in our REVEAL-1 and REMAIN-1 studies, and Rejuva advancing toward first-in-human studies, we believe 2025 will be a pivotal year – one that marks a major transformation in obesity and T2D treatment. We remain laser-focused on our efforts to deliver the innovations that will change the trajectory of these diseases for millions worldwide.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health price target lowered to $6 from $13 at BofA
- Fractyl Health Reprioritizes Focus on REMAIN-1 Study
- Fractyl Health announces increased focus on Revita, Rejuva programs
- Fractyl Health’s Promising Progress in Weight Management
- Fractyl Health announces clinical results from first patient in REVEAL-1 cohort